Stoke Therapeutics, Inc. (STOK) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CorMedix, Inc.

Invivyd, Inc.

Carisma Therapeutics, Inc.

Stoke Therapeutics, Inc.

Foghorn Therapeutics, Inc.

Fate Therapeutics, Inc.

Taysha Gene Therapies, Inc.

Vigil Neuroscience, Inc.

Neoleukin Therapeutics, Inc.

Larimar Therapeutics, Inc.

Ikena Oncology, Inc.

Why is Stoke Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 2.87%

The company has been able to generate a Return on Equity (avg) of 2.87% signifying low profitability per unit of shareholders funds

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 277.79%, its profits have risen by 138.5% ; the PEG ratio of the company is 0.4

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Stoke Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Stoke Therapeutics, Inc.

309.82%

1.72

72.76%

S&P 500

16.12%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

190.43%

EBIT Growth (5y)

20.58%

EBIT to Interest (avg)

-67.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.23

Tax Ratio

2.48%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

2.87%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.30

EV to EBIT

62.30

EV to EBITDA

53.91

EV to Capital Employed

27.02

EV to Sales

8.24

PEG Ratio

0.35

Dividend Yield

ROCE (Latest)

43.37%

ROE (Latest)

13.17%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET SALES(HY)

At USD 24.45 MM has Grown at 151.4%

OPERATING CASH FLOW(Y)

Highest at USD 52.85 MM

RAW MATERIAL COST(Y)

Fallen by -17.56% (YoY

NET PROFIT(9M)

Higher at USD 51.05 MM

-18What is not working for the Company

INTEREST(9M)

At USD 0.01 MM has Grown at inf%

NET SALES(Q)

At USD 10.63 MM has Fallen at -78.72%

DEBT-EQUITY RATIO (HY)

Highest at -79.04 %

OPERATING PROFIT(Q)

Lowest at USD -42.1 MM

PRE-TAX PROFIT(Q)

Lowest at USD -39.62 MM

NET PROFIT(Q)

Lowest at USD -38.35 MM

EPS(Q)

Lowest at USD -0.65

Here's what is working for Stoke Therapeutics, Inc.

Operating Cash Flow

Highest at USD 52.85 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost

Fallen by -17.56% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Stoke Therapeutics, Inc.

Interest

At USD 0.01 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales

At USD 10.63 MM has Fallen at -78.72%

over average net sales of the previous four periods of USD 49.97 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -39.62 MM has Fallen at -394.82%

over average net sales of the previous four periods of USD 13.44 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -38.35 MM has Fallen at -392.26%

over average net sales of the previous four periods of USD 13.12 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -42.1 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -39.62 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -38.35 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.65

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Highest at -79.04 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio